Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 885823 | ISIN: US3755581036 | Ticker-Symbol: GIS
Tradegate
25.07.25 | 20:32
98,96 Euro
0,00 % 0,00
1-Jahres-Chart
GILEAD SCIENCES INC Chart 1 Jahr
5-Tage-Chart
GILEAD SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
98,6998,8626.07.
98,7298,9825.07.

Aktuelle News zur GILEAD SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrWhy Gilead Sciences Stock Just Popped28
FrGilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales7
FrEurope's CHMP gives thumbs-up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo5
FrGilead upgraded to Buy at Needham on new HIV drug15
Fr5 stocks to watch on Friday: PSX, EW, NEM, GILD, CNC7
FrThis Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday27
FrGilead wins EU backing for twice-yearly HIV PrEP therapy5
GILEAD SCIENCES Aktie jetzt für 0€ handeln
FrGilead: Lenacapavir erhält positives CHMP-Votum zur HIV-Prävention18
FrGilead's lenacapavir receives positive CHMP opinion for HIV prevention3
FrGilead Sciences, Inc.: Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention400- If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV PrEP Option in the European Union - - Positive Opinion Also Received for EMA's EU-M4all Procedure, Designed to Facilitate...
► Artikel lesen
DoErgebnisse, Hackerangriffe, Wetten, Trends & News live aus Silicon Valley - Calling USA
MiGilead Sciences: Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic327NORTHAMPTON, MA / ACCESS Newswire / July 23, 2025 / In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed...
► Artikel lesen
MiWhat to Expect From Gilead Sciences' Q2 2025 Earnings Report25
MoHookipa, having sold off vaccines to Gilead, opts to wind down16
19.07.Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector17
18.07.HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale7
18.07.HOOKIPA Pharma to delist from Nasdaq amid asset sale to Gilead21
15.07.Gilead reaches $202M settlement over HIV drug speaker program10
15.07.Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock11
15.07.Fighting Disease Requires More Than Just the Right Drug: Gilead4
Weiter >>
364 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
6,1,17